Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2792300 | Bone Reports | 2016 | 6 Pages |
Abstract
This review clearly points out a lack of adequate clinical methods for fracture risk prediction in patients with femoral metastases. Today's golden standard, the Mirels' score leads to an overtreatment. Whereas, engineering methods showed high potential but require a clinical validation. In future definition of patient-specific, quantitative risk factor based modelling methods could serve as useful decision support for individualized treatment strategies in patients with a metastatic lesion.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Emir Benca, Janina M. Patsch, Winfried Mayr, Dieter H. Pahr, Reinhard Windhager,